Trial · NCT02655510

Use of F-652 in Patients With Alcoholic Hepatitis

NCT02655510, Phase 1, Phase 2, Completed, Mayo Clinic; results first posted 2019-09-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Use of F-652 in Patients With Alcoholic Hepatitis. Trials, record NCT02655510. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02655510

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Use of F-652 in Patients With Alcoholic Hepatitis
NCT number: NCT02655510
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 18 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Alcoholic Hepatitis
Interventions: F-652
First posted: 2016-01-14
Last updated: 2019-09-09
Results first posted: 2019-09-09

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Number of Subjects With Unexpected Serious Adverse Events.	From day 1 up to 42 days following administration of last dose of study drug	The count of subjects who experience serious adverse events

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Number of Subjects With Unexpected Serious Adverse Events.	From day 1 up to 42 days following administration of last dose of study drug		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Units
The Number of Subjects With Unexpected Serious Adverse Events.	Period 1: F-652 10 μg/kg	Participants
The Number of Subjects With Unexpected Serious Adverse Events.	Period 2: F-652 30 μg/kg	Participants
The Number of Subjects With Unexpected Serious Adverse Events.	Period 3: F-652 45 μg/kg	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Period 1: F-652 10 μg/kg	6
Overall Study	STARTED	Period 2: F-652 30 μg/kg	6
Overall Study	STARTED	Period 3: F-652 45 μg/kg	6
Overall Study	COMPLETED	Period 1: F-652 10 μg/kg	6
Overall Study	COMPLETED	Period 2: F-652 30 μg/kg	6
Overall Study	COMPLETED	Period 3: F-652 45 μg/kg	6
Overall Study	NOT COMPLETED	Period 1: F-652 10 μg/kg	0
Overall Study	NOT COMPLETED	Period 2: F-652 30 μg/kg	0
Overall Study	NOT COMPLETED	Period 3: F-652 45 μg/kg	0

Source ClinicalTrials.gov

Adverse events45

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pruritus	Skin and subcutaneous tissue disorders	Period 1: F-652 10 μg/kg	0	6	0
other	Pruritus	Skin and subcutaneous tissue disorders	Period 2: F-652 30 μg/kg	2	6	3
other	Pruritus	Skin and subcutaneous tissue disorders	Period 3: F-652 45 μg/kg	1	6	1
other	Leukocytosis	Investigations	Period 1: F-652 10 μg/kg	0	6	0
other	Leukocytosis	Investigations	Period 2: F-652 30 μg/kg	1	6	1
other	Leukocytosis	Investigations	Period 3: F-652 45 μg/kg	0	6	0
other	Arrhythmia	Cardiac disorders	Period 1: F-652 10 μg/kg	0	6	0
other	Arrhythmia	Cardiac disorders	Period 2: F-652 30 μg/kg	0	6	0
other	Arrhythmia	Cardiac disorders	Period 3: F-652 45 μg/kg	1	6	1
other	Fever	General disorders	Period 1: F-652 10 μg/kg	0	6	0

1 to 10 of 45Source ClinicalTrials.gov

See all 45 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Period 1: F-652 10 μg/kg	0	6
Total, all-cause mortality	Period 2: F-652 30 μg/kg	1	6
Total, all-cause mortality	Period 3: F-652 45 μg/kg	0	6
Total, other adverse events	Period 1: F-652 10 μg/kg	2	6
Total, other adverse events	Period 2: F-652 30 μg/kg	5	6
Total, other adverse events	Period 3: F-652 45 μg/kg	4	6
Total, serious adverse events	Period 1: F-652 10 μg/kg	0	6
Total, serious adverse events	Period 2: F-652 30 μg/kg	0	6
Total, serious adverse events	Period 3: F-652 45 μg/kg	0	6

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37011138	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02655510

GET https://conductscience.org/api/trials/v1/NCT02655510/events?page=2

API reference For AI assistants